Quinidine Gluconate

(quinidine)

ApprovedSmall molecule

Quinidine Gluconate is a small molecule that works as a Sodium Channel Alpha Subunit Blocker; Sodium Channel Alpha Subunit Blocker.[2] It is being used across 12 indications, with its most advanced program in Approved.[1]

Quinidine Gluconate is one of 382 small molecule programs targeting Constipation. It is currently in Approved.

Indications

Total Trials

Active Trials

381

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrhythmiaActive, not recruiting

Cardiac ArrestActive, not recruiting

Hepatitis B Virus InfectionApproved

Depressive DisorderApproved

Migraine DisorderApproved

Amyotrophic Lateral SclerosisApproved

Non-Alcoholic SteatohepatitisApproved

Multiple SclerosisApproved

Atrial FibrillationActive, not recruiting

Major Depressive DisorderApproved

Cardiac ArrhythmiaApproved

Active, not recruiting

Cardiac ArrestPhase 3

Active, not recruiting

Hepatitis B Virus InfectionApproved

Approved

Depressive DisorderApproved

Approved

Migraine DisorderApproved

Approved

Amyotrophic Lateral SclerosisApproved

Approved

Non-Alcoholic SteatohepatitisApproved

Approved

Multiple SclerosisApproved

Approved

Atrial FibrillationPhase 3

Active, not recruiting

Major Depressive DisorderApproved

Approved

Showing 10 of 11 indications

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Quinidine Gluconate

WWyeth-Lederle Vaccines

Approved

19 2

Betaseron

Bayer

Preclinical

16 3

Kesimpta

Novartis

Preclinical

15 4

Tysabri

Biogen

Preclinical

14 5

Avonex

EMD Serono

Preclinical

22 6

Flomax

Sanofi

Preclinical

1 7

Pred Forte

Myfortic

Novantrone

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction6 trials

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06704763·27 enrolled

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT05594602·36 enrolled

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT03755778·72 enrolled

Show 3 more trials

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT04783753·72 enrolled

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT06847464·48 enrolled

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT03610945·48 enrolled

Tics3 trials

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171624·42 enrolled

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06974565·16 enrolled

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01533155·214 enrolled

Cardiac Arrest1 trial

Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)

Completed·UUniversity of Washington·Phase 3·NCT00000464

Atrial Fibrillation1 trial

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000556

Lenalidomide1 trial

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01712828·31 enrolled

6 more indications

Single Dose1 trial

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06493409·32 enrolled

CAR1 trial

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)

Completed·UUniversity of Utah·Phase 3·NCT00000518

Female1 trial

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05444556·113 enrolled

Idiopathic Ventricular Fibrillation1 trial

Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation

Unknown status·—·Phase 2·NCT05593757·24 enrolled

Dapagliflozin1 trial

A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06979388·14 enrolled

Unspecified2 trials

Empiric Quinidine for Asymptomatic Brugada Syndrome

Withdrawn·IInternational Registry of Asymptomatic Brugada Syndrome·Phase 2/3·NCT00789165

A Study to Evaluate the Effect of Genotype on LY2216684

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01460381·18 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

DURAQUIN

NDA NDA017917

Jan 1, 1982

QUINAGLUTE

NDA NDA016647

Jan 1, 1982

QUINIDEX

NDA NDA012796

Feb 10, 1989

QUINIDINE GLUCONATE

NDA NDA007529

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for quinidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — quinidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for quinidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA007529). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sodium Channel Alpha Subunit Blocker; Sodium Channel Alpha Subunit Blocker[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWyeth-Lederle Vaccines

Quinidine Gluconate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Interaction6 trials

Tics3 trials

Cardiac Arrest1 trial

Atrial Fibrillation1 trial

Lenalidomide1 trial

Single Dose1 trial

CAR1 trial

Female1 trial

Idiopathic Ventricular Fibrillation1 trial

Dapagliflozin1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News